PAVmed Historical Income Statement

PAVMZ Stock

USD 0.01 0 20.20%

Historical analysis of PAVmed Series income statement accounts such as Total Operating Expenses of 78.3 M, Depreciation And Amortization of 3.5 M, Tax Provision of 0.0 or Interest Income of 431.8 K can show how well PAVmed Series Z performed in making a profits. Evaluating PAVmed Series income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of PAVmed Series's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining PAVmed Series Z latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether PAVmed Series Z is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Series Z. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

About PAVmed Income Statement Analysis

PAVmed Series Z Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to PAVmed Series shareholders. The income statement also shows PAVmed investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

PAVmed Series Income Statement Chart

At this time, PAVmed Series' Interest Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 37.4 M in 2025, despite the fact that Operating Income is likely to grow to (58.8 M).

Selling General Administrative Operating Income Other Operating Expenses Ebit Research Development

Operating Income

Operating Income is the amount of profit realized from PAVmed Series Z operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of PAVmed Series Z is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of PAVmed Series Z. It is also known as PAVmed Series overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from PAVmed Series' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into PAVmed Series Z current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Series Z. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

PAVmed Series income statement Correlations

	Selling General Administrative	Operating Income	Income Before Tax	Net Income	Other Operating Expenses	Ebit	Research Development	Ebitda	Total Operating Expenses	Depreciation And Amortization	Total Other Income Expense Net	Net Interest Income	Interest Income	Total Revenue	Gross Profit	Net Income From Continuing Ops	Reconciled Depreciation	Income Tax Expense	Minority Interest	Cost Of Revenue	Selling And Marketing Expenses	Non Operating Income Net Other
Selling General Administrative		-0.98	-0.98	-0.96	1.0	-0.98	0.91	-0.98	1.0	0.88	-0.83	0.11	-0.57	-0.71	-0.87	-0.98	0.9	-0.69	0.93	0.86	0.94	0.56
Operating Income	-0.98		1.0	0.99	-0.98	1.0	-0.95	1.0	-0.98	-0.83	0.82	-0.1	0.58	0.71	0.86	0.99	-0.85	0.62	-0.89	-0.79	-0.94	-0.43
Income Before Tax	-0.98	1.0		0.99	-0.98	1.0	-0.95	1.0	-0.98	-0.83	0.87	-0.06	0.56	0.74	0.89	0.99	-0.85	0.62	-0.88	-0.8	-0.93	-0.44
Net Income	-0.96	0.99	0.99		-0.95	0.99	-0.96	0.99	-0.96	-0.78	0.86	-0.01	0.54	0.74	0.87	0.98	-0.8	0.53	-0.83	-0.73	-0.9	-0.37
Other Operating Expenses	1.0	-0.98	-0.98	-0.95		-0.98	0.89	-0.98	1.0	0.9	-0.81	0.14	-0.57	-0.68	-0.86	-0.98	0.92	-0.72	0.95	0.88	0.95	0.58
Ebit	-0.98	1.0	1.0	0.99	-0.98		-0.94	1.0	-0.98	-0.84	0.85	-0.1	0.59	0.71	0.86	1.0	-0.85	0.63	-0.88	-0.8	-0.94	-0.44
Research Development	0.91	-0.95	-0.95	-0.96	0.89	-0.94		-0.95	0.91	0.64	-0.81	0.05	-0.59	-0.78	-0.84	-0.92	0.66	-0.4	0.72	0.6	0.83	0.33
Ebitda	-0.98	1.0	1.0	0.99	-0.98	1.0	-0.95		-0.98	-0.83	0.86	-0.1	0.59	0.72	0.87	0.99	-0.84	0.62	-0.88	-0.79	-0.93	-0.43
Total Operating Expenses	1.0	-0.98	-0.98	-0.96	1.0	-0.98	0.91	-0.98		0.88	-0.81	0.13	-0.58	-0.69	-0.86	-0.98	0.9	-0.69	0.94	0.86	0.95	0.56
Depreciation And Amortization	0.88	-0.83	-0.83	-0.78	0.9	-0.84	0.64	-0.83	0.88		-0.67	0.15	-0.41	-0.4	-0.67	-0.87	0.98	-0.86	0.97	0.97	0.92	0.69
Total Other Income Expense Net	-0.83	0.82	0.87	0.86	-0.81	0.85	-0.81	0.86	-0.81	-0.67		0.09	0.43	0.85	0.92	0.84	-0.71	0.56	-0.68	-0.67	-0.72	-0.4
Net Interest Income	0.11	-0.1	-0.06	-0.01	0.14	-0.1	0.05	-0.1	0.13	0.15	0.09		-0.8	0.26	0.12	-0.1	0.18	-0.28	0.19	0.22	0.15	0.19
Interest Income	-0.57	0.58	0.56	0.54	-0.57	0.59	-0.59	0.59	-0.58	-0.41	0.43	-0.8		0.28	0.39	0.57	-0.47	0.36	-0.49	-0.45	-0.52	-0.27
Total Revenue	-0.71	0.71	0.74	0.74	-0.68	0.71	-0.78	0.72	-0.69	-0.4	0.85	0.26	0.28		0.94	0.69	-0.48	0.35	-0.51	-0.45	-0.53	-0.27
Gross Profit	-0.87	0.86	0.89	0.87	-0.86	0.86	-0.84	0.87	-0.86	-0.67	0.92	0.12	0.39	0.94		0.86	-0.74	0.62	-0.75	-0.72	-0.76	-0.46
Net Income From Continuing Ops	-0.98	0.99	0.99	0.98	-0.98	1.0	-0.92	0.99	-0.98	-0.87	0.84	-0.1	0.57	0.69	0.86		-0.89	0.67	-0.91	-0.84	-0.96	-0.47
Reconciled Depreciation	0.9	-0.85	-0.85	-0.8	0.92	-0.85	0.66	-0.84	0.9	0.98	-0.71	0.18	-0.47	-0.48	-0.74	-0.89		-0.89	0.99	0.99	0.93	0.71
Income Tax Expense	-0.69	0.62	0.62	0.53	-0.72	0.63	-0.4	0.62	-0.69	-0.86	0.56	-0.28	0.36	0.35	0.62	0.67	-0.89		-0.86	-0.94	-0.76	-0.71
Minority Interest	0.93	-0.89	-0.88	-0.83	0.95	-0.88	0.72	-0.88	0.94	0.97	-0.68	0.19	-0.49	-0.51	-0.75	-0.91	0.99	-0.86		0.97	0.95	0.69
Cost Of Revenue	0.86	-0.79	-0.8	-0.73	0.88	-0.8	0.6	-0.79	0.86	0.97	-0.67	0.22	-0.45	-0.45	-0.72	-0.84	0.99	-0.94	0.97		0.9	0.75
Selling And Marketing Expenses	0.94	-0.94	-0.93	-0.9	0.95	-0.94	0.83	-0.93	0.95	0.92	-0.72	0.15	-0.52	-0.53	-0.76	-0.96	0.93	-0.76	0.95	0.9		0.61
Non Operating Income Net Other	0.56	-0.43	-0.44	-0.37	0.58	-0.44	0.33	-0.43	0.56	0.69	-0.4	0.19	-0.27	-0.27	-0.46	-0.47	0.71	-0.71	0.69	0.75	0.61

Click cells to compare fundamentals

PAVmed Series Account Relationship Matchups

PAVmed Series income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	53K	5.8M	1.3M	589K	677.4K	1.2M
Selling General Administrative	12.4M	25.6M	41.0M	30.9M	35.6M	37.4M
Operating Income	(23.4M)	(54.4M)	(90.9M)	(68.8M)	(61.9M)	(58.8M)
Income Before Tax	(35.9M)	(56.1M)	(103.2M)	(79.3M)	(71.3M)	(67.8M)
Net Income	(34.3M)	(50.3M)	(101.3M)	(64.2M)	(57.8M)	(54.9M)
Other Operating Expenses	23.4M	54.9M	91.3M	71.2M	81.9M	86.0M
Ebit	(35.8M)	(56.1M)	(102.0M)	(78.7M)	(70.8M)	(67.3M)
Research Development	11.0M	19.8M	25.5M	14.3M	16.4M	10.6M
Ebitda	(35.8M)	(55.9M)	(99.4M)	(75.7M)	(68.2M)	(64.8M)
Total Operating Expenses	23.4M	54.3M	87.7M	64.8M	74.6M	78.3M
Depreciation And Amortization	23K	226K	2.6M	2.9M	3.4M	3.5M
Total Other Income Expense Net	(12.5M)	(1.7M)	(12.2M)	(10.5M)	(9.4M)	(9.0M)
Net Interest Income	(713K)	(523K)	(1.3M)	(448K)	(515.2K)	(541.0K)
Interest Income	5.6M	591.3K	169K	505K	454.5K	431.8K
Gross Profit	(23K)	(85K)	(3.2M)	(4.0M)	(3.6M)	(3.4M)
Net Income From Continuing Ops	(35.9M)	(56.1M)	(103.2M)	(86.4M)	(77.8M)	(73.9M)
Reconciled Depreciation	23K	226K	2.5M	2.9M	3.4M	3.5M
Income Tax Expense	(1.6M)	(5.8M)	(1.9M)	(13.0B)	(11.7B)	(11.1B)
Minority Interest	(1.6M)	5.8M	14.3M	15.8M	18.2M	19.1M
Cost Of Revenue	23K	585K	3.6M	6.4M	7.4M	7.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for PAVmed Stock Analysis

When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

PAVmed Historical Income Statement

About PAVmed Income Statement Analysis

PAVmed Series Income Statement Chart

Operating Income

Other Operating Expenses

PAVmed Series income statement Correlations

PAVmed Series Account Relationship Matchups

High Positive Relationship

High Negative Relationship

PAVmed Series income statement Accounts

Also Currently Popular

Additional Tools for PAVmed Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Income Before Tax	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Ebit	+ 1.0	Income Before Tax

Net Income From Continuing Ops	- 0.98	Total Operating Expenses
Total Operating Expenses	- 0.98	Ebitda
Total Operating Expenses	- 0.98	Ebit
Net Income From Continuing Ops	- 0.98	Other Operating Expenses
Ebitda	- 0.98	Other Operating Expenses
Ebit	- 0.98	Other Operating Expenses